---
schema_version: "secwatch.filing_event.v1"
accession: "0001140361-25-040774"
form_type: "8-K"
ticker: "RCKT"
cik: "0001281895"
company_name: "ROCKET PHARMACEUTICALS, INC."
filed_at: "2025-11-06T23:59:59+00:00"
generated_at: "2026-05-16T23:23:52.286477+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Rocket Pharma Q3 net loss $50.3M; KRESLADI PDUFA March 2026; Danon trial to resume 1H 2026

## Summary
- Q3 net loss $50.3M ($0.45/share), down from $66.7M ($0.71) YoY; R&D expenses $34.1M vs $42.3M.
- Cash, equivalents, investments $222.8M; runway expected into Q2 2027.
- FDA accepted KRESLADI (marne-cel) BLA resubmission for severe LAD-I; PDUFA target March 28, 2026.
- Phase 2 trial of RP-A501 for Danon disease to resume dosing in 1H 2026 after FDA lifted clinical hold.
- Appointed Dr. Syed Rizvi as CMO, Christopher Stevens as COO, Sarbani Chaudhuri as Chief Commercial & Medical Affairs Officer.

## SEC filing metadata
- accession: 0001140361-25-040774
- form_type: 8-K
- ticker: RCKT
- cik: 0001281895
- company_name: ROCKET PHARMACEUTICALS, INC.
- filed_at: 2025-11-06T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1281895/000114036125040774/0001140361-25-040774-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1281895/000114036125040774/ef20058531_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001140361-25-040774
- JSON: https://secwatch.observer/filing/0001140361-25-040774.json
- Plain text: https://secwatch.observer/filing/0001140361-25-040774.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.